It signifies a possible situational intervention with fast onset that doesn't have the dependence profile of benzodiazepines. Regulatory standing as of 2025–2026 warrants verification with present-day FDA databases.D-cycloserine, a partial NMDA agonist, has become analyzed for a CBT augmentation system — with some evidence that administrati… Read More